Drug & intervention

tamoxifen 20 MG

RxCUI 330595

Clinical trials5

Recruiting3

Related conditions12

Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…

Clinical trials

5 shown

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast CancerNCT07287098 · 2026-05-13

Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast CancerNCT05982093 · 2023-02-03

Impact of Neoadjuvant Hormonal Therapy on the Surgical Management of Extensive Ductal Carcinomas in SituNCT04666961 · 2021-02-03

Therapeutic Dose Monitoring (TDM) of TamoxifenNCT05133674 · 2022-04-04

Genetic Study of CYP2D6 Enzyme and Therapeutic Drug Monitoring of TamoxifenNCT03582865 · 2019-09-01

Conditions being studied

Breast Cancer3 Breast Carcinoma1 Breast Neoplasms1 Breast Tumors1 Cancer of Breast1 Ductal Carcinoma in Situ1 Extensive Disease1 HER2-negative Breast Cancer1 Hormone Receptor Positive Tumor1 Malignant Neoplasm of Breast1 Mastectomy1 Premenopausal Breast Cancer1

Research locations

MontpellierFrance2 AngersFrance1 AtlantaGeorgia, United States1 BarcelonaSpain1 BerlinGermany1 BirminghamAlabama, United States1 BochumGermany1 BonnGermany1 BordeauxFrance1 BostonMassachusetts, United States1 BrestFrance1 BrusselsBelgium1

Leading sponsors

Assiut University1 Eli Lilly and Company1 Institut Cancerologie de l'Ouest1 Karolinska University Hospital1 SOLTI Breast Cancer Research Group1

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.